Skip to main content
. 2010 Jul 19;12(4):R147. doi: 10.1186/ar3089

Figure 1.

Figure 1

Clinical effects of free or liposomal DxM-P in adjuvant arthritis (Experiment 1). Effect of treatment with PBS-liposomes, free DxM-P (3 × 1 mg/kg; Days 14, 15 and 16), or liposomal DxM-P (3 × 1 mg/kg; Days 14, 15 and 16) on arthritis score (a), paw volume (b), and body weight (c); all arthritic groups were normalized to the same mean value for each parameter on Day 14 (n = 6 each). The inserts show the area under the curve (AUC) from Day 0 to Day 30 for the arthritis score (a) and the paw volume (b); dashed line: healthy control levels. For all treatment groups: + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. AA/PBS-liposomes; * P ≤ 0.05 vs. AA/DxM-P; For AA/liposomal DxM-P: o P ≤ 0.05, oo P ≤ 0.01 vs. healthy controls; all Mann Whitney U-test; ↑ I. v. administration of PBS, PBS-liposomes, free DxM-P, or liposomal DxM-P.